Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of major shareholdings)
11 January 2024 - 9:00AM
Press release Biocartis Group NV: Disclosure of transparency
notification (Article 14, first paragraph, of the Act of 2 May 2007
on the disclosure of major shareholdings)
BIOCARTIS GROUP NV (Euronext Brussels: BCART)
PRESS RELEASE - REGULATED INFORMATION - 10 January
2024, 23:00 CET
Disclosure of transparency
notification
(Article 14, first paragraph, of the Act of
2 May 2007 on the disclosure of major shareholdings)
1. Summary of notice
BIOCARTIS GROUP NV received a transparency notification on
January 5, 2024, showing that JPMorgan Chase & Co., with
registered office at c/o CT Corporation, 1209 Orange Street,
Wilmington, DE19801, USA, following the acquisition of shares on
January 3, 2024, exceeds the participation threshold of 5%.
2. Contents of the
notification
The notification dated 5 January 2024 contains the
following information:
- Reason
for the notification: Acquisition or disposal of voting
securities or voting rights.
-
Notification by: a parent undertaking or a
controlling person.
-
Person(s) required to notify : JPMorgan Chase
& Co., with registered office at c/o CT Corporation, 1209
Orange Street, Wilmington, DE19801, USA.
-
Date on which the threshold is crossed:
03-01-2024
-
Threshold exceeded (in %): 5%
-
Denominator: 93,915,910
-
Notification details:
A) Voting rights attached to voting
securities |
Holders of voting rights |
Previous notice |
After the transaction |
Number of voting rights |
Number of voting rights |
% voting rights |
Related to securities |
Regardless of the effects |
Related to securities |
Regardless of the effects |
JPMorgen Chase & Co. |
0 |
0 |
0 |
0% |
0% |
JP Morgan Securities PLC |
0 |
4,837,106 |
0 |
5.15% |
0% |
JP Morgan Securities LLC |
0 |
5,000 |
0 |
0.01% |
0% |
TOTAL |
|
4,842,106 |
0 |
5.16% |
0% |
B) Similar financial instruments |
After the transaction |
Holders of equivalent financial instruments |
Type of financial instrument |
Expiration date |
Exercise period or date |
# voting rights that may be acquired if the instrument is
exercised |
% of voting rights |
Settlement |
JP Morgan Securities PLC |
Equity SWAP |
|
04/03/2024 – 04/02/2024 |
84,927 |
0.09% |
cash |
JP Morgan Securities LLC |
Right to take back lent shares |
|
|
15,712 |
0.02% |
physically |
|
|
|
|
100,639 |
0.11% |
|
|
|
|
|
|
|
|
|
TOTAL (A & B |
# voting rights |
% of voting rights |
|
|
|
|
|
4,942,745 |
5.26% |
|
-
chain of controlled undertakings through which the holding
is effectively held:
JPMorgan Chase &
Co.JPMorgan Chase Bank, National Association (100%)JP Morgan
International Finance Limited (100%)JP Morgan Capital Holdings
Limited (100%)JP Morgan Securities plc (100%)
JPMorgan Chase &
Co.JPMorgan Chase Holdings LLC (100%)JP Morgan Broker-Dealer
Holdings Inc. (100%)JP Morgan Securities LLC (100%)
3. Miscellaneous
This press release can be consulted on the website
of BIOCARTIS GROUP NV via this link Press releases | Biocartis
Group NV.
--- END ---
More information:
Investor Relations Biocartis Group
NVe-mail info@biocartisgroupnv.be
Biocartis and Idylla™ are registered trademarks in
Europe, the United States and other countries. The Biocartis and
Idylla™ trademark and logo are used trademarks owned by Biocartis.
Please refer to the product labeling for applicable intended uses
for each individual Biocartis product. This press release is not
for distribution, directly or indirectly, in any jurisdiction where
to do so would be unlawful. Any persons reading this press release
should inform themselves of and observe any such restrictions.
Biocartis takes no responsibility for any violation of any such
restrictions by any person. This press release does not constitute
an offer or invitation for the sale or purchase of securities in
any jurisdiction. No securities of Biocartis may be offered or sold
in the United States of America absent registration with the United
States Securities and Exchange Commission or an exemption from
registration under the U.S. Securities Act of 1933, as amended.
Forward-looking statements
Certain statements, beliefs and opinions in this
press release are forward-looking, which reflect the Company's or,
as appropriate, the Company directors' or managements' current
expectations and projections concerning future events such as the
Company's results of operations, financial condition, liquidity,
performance, prospects, growth, strategies and the industry in
which the Company operates. By their nature, forward-looking
statements involve a number of risks, uncertainties, assumptions
and other factors that could cause actual results or events to
differ materially from those expressed or implied by the
forward-looking statements. These risks, uncertainties, assumptions
and factors could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of
factors including, but not limited to, changes in demand,
competition and technology, can cause actual events, performance or
results to differ significantly from any anticipated development.
Forward-looking statements contained in this press release
regarding past trends or activities are not guarantees of future
performance and should not be taken as a representation that such
trends or activities will continue in the future. In addition, even
if actual results or developments are consistent with the
forward-looking statements contained in this press release, those
results or developments may not be indicative of results or
developments in future periods. No representations and warranties
are made as to the accuracy or fairness of such forward-looking
statements. As a result, the Company expressly disclaims any
obligation or undertaking to release any updates or revisions to
any forward-looking statements in this press release as a result of
any change in expectations or any change in events, conditions,
assumptions or circumstances on which these forward-looking
statements are based, except if specifically required to do so by
law or regulation. Neither the Company nor its advisers or
representatives nor any of its subsidiary undertakings or any such
person's officers or employees guarantees that the assumptions
underlying such forward-looking statements are free from errors nor
does either accept any responsibility for the future accuracy of
the forward-looking statements contained in this press release or
the actual occurrence of the forecasted developments. You should
not place undue reliance on forward-looking statements, which speak
only as of the date of this press release.
Biocartis Group NV (EU:BCART)
Historical Stock Chart
From Aug 2024 to Sep 2024
Biocartis Group NV (EU:BCART)
Historical Stock Chart
From Sep 2023 to Sep 2024